Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 116

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 116
---
ABILITIES 
     7,465  
     18,862 

    COMMITMENTS AND CONTINGENCIES 

    Redeemable common stock, $0.001 par value; 0 and 75,697 shares issued and outstanding, respectively (Note 9) 
     -  
     799 

    STOCKHOLDERS’ EQUITY 

    Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding 
     -  
     - 
  
    Common stock, $0.001 par value, 200,000,000 shares authorized, 22,280,451 and 17,950,776 shares issued and outstanding, respectively 
     22  
     18 
  
    Additional paid-in capital 
     195,754  
     159,143 
  
    Accumulated other comprehensive loss 
     (575) 
     (799)
  
    Accumulated deficit 
     (163,104) 
     (121,022)
  
    TOTAL STOCKHOLDERS’ EQUITY 
     32,097  
     37,340 

    TOTAL LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ EQUITY 
    $39,562  
    $57,001 

See accompanying notes to these consolidated financial
statements.

F-3

INMUNE BIO INC. 

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS

FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

(In
thousands, except share and per share amounts)

    2024  
    2023 
  
    REVENUE 
    $14  
    $155 

    OPERATING EXPENSES 

    General and administrative 
     9,483  
     9,623 
  
    Research and development 
     33,166  
     20,273 
  
    Total operating expenses 
     42,649  
     29,896 

    LOSS FROM OPERATIONS 
     (42,635) 
     (29,741)

    OTHER INCOME (EXPENSE), NET 

    Other income (expense), net 
     553  
     (267)
  
    Total other income (expense), net